Literature DB >> 18379026

[Bone metastases in lung cancer].

Asuka Tsuya1, Masahiro Fukuoka.   

Abstract

The skeleton is one of the most common sites of metastasis in patients with lung cancer. It has been reported that the incidence of bone metastases in lung cancer patients is approximately 30-40%, and the median survival time (MST) of patients with such metastases is 6-7 months. Metastatic bone disease leads to various complications or skeletal related events (SREs), including pain, pathologic fracture, vertebral deformity and collapse, spinal cord compression, and hypercalcemia of malignancy. These events often lead to rapid deterioration in quality of life (QOL). The fundamental treatment for bone metastasis from advanced lung cancer is disease control by systemic chemotherapy. So the prevention and treatment of bone metastases is mainly dependent on an effective treatment against lung cancer itself. As a direct treatment for bone metastases, radiation therapy, surgery and bisphosphonates are the main ways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18379026     DOI: CliCa0804455459

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  4 in total

1.  Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice.

Authors:  Satoshi Sakaguchi; Hisatsugu Goto; Masaki Hanibuchi; Shinsaku Otsuka; Hirokazu Ogino; Soji Kakiuchi; Hisanori Uehara; Seiji Yano; Yasuhiko Nishioka; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2010-05-13       Impact factor: 5.150

2.  Application of radiofrequency thermocoagulation combined with adriamycin injection in dorsal root ganglia for controlling refractory pain induced by rib metastasis of lung cancer (a STROBE-compliant article).

Authors:  Guang-Lun Xie; Da-Peng Guo; Zhi-Gang Li; Chang Liu; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

3.  Clinical utility of 188Rhenium-hydroxyethylidene-1,1-diphosphonate as a bone pain palliative in multiple malignancies.

Authors:  Ajit S Shinto; Madhava B Mallia; Mythili Kameswaran; K K Kamaleshwaran; Jephy Joseph; E R Radhakrishnan; Indira V Upadhyay; R Subramaniam; Madhu Sairam; Sharmila Banerjee; Ashutosh Dash
Journal:  World J Nucl Med       Date:  2018 Oct-Dec

4.  Retrospective study on the efficacy of bisphosphonates in tyrosine kinase inhibitor-treated patients with non-small cell lung cancer exhibiting bone metastasis.

Authors:  Xiaoxian Cui; Shaoli Li; Jincui Gu; Ziying Lin; Bipeng Lai; Lixia Huang; Jinlun Feng; Baomo Liu; Yanbin Zhou
Journal:  Oncol Lett       Date:  2019-09-16       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.